doi:10.3969/j.issn.1673-8640.2023.12.008

Abstract

CLC Number:

R446.1

Figures/Tables 4

References 13

[1]	BECK L H Jr, BONEGIO R G, LAMBEAU G, et al. M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy[J]. N Engl J Med, 2009, 361(1):11-21. DOI URL
[2]	HOFSTRA J M, BECK L H J R, BECK D M, et al. Anti-phospholipase A receptor antibodies correlate with clinical status in idiopathic membranous nephropathy[J]. Clin J Am Soc Nephrol, 2011, 6(6):1286-1291. DOI URL
[3]	刘莎莎, 张丽, 李素华, 等. 血清抗磷脂酶A2受体抗体在特发性膜性肾病诊断中意义[J]. 中华实用诊断与治疗杂志, 2016, 30(4):405-406.
[4]	FLOEGE J, BARBOUR S J, CATTRAN D C, et al. Management and treatment of glomerular diseases(part 1) :conclusions from a kidney disease:improving global outcomes(KDIGO) controversies conference[J]. Kidney Int, 2019, 95(2):268-280. DOI URL
[5]	YY/T 1789.2-2021. 体外诊断检验系统性能评价方法第2部分:正确度[S].
[6]	YY/T 1789.3-2022. 体外诊断检验系统性能评价方法第3部分:检出限与定量限[S].
[7]	COUSER W G. Primary membranous nephropathy[J]. Clin J Am Soc Nephrol, 2017, 12(6):983-997. DOI URL
[8]	伍敏, 魏青, 刘必成. 原发性膜性肾病诊断及治疗新进展[J]. 中国实用内科杂志, 2023, 43(3):183-187.
[9]	VAN DE LOGT A E, FRESQUET M, WETZELS J F, et al. The anti-PLA2R antibody in membranous nephropathy:what we know and what remains a decade after its discovery[J]. Kidney Int, 2019, 96(6):1292-1302. DOI URL
[10]	CATTRAN D C, BRENCHLEY P E. Membranous nephropathy:integrating basic science into improved clinical management[J]. Kidney Int, 2017, 91(3):566-574. DOI URL
[11]	DE VRIESE A S, GLASSOCK R J, NATH K A, et al. A proposal for a serology-based approach to membranous nephropathy[J]. J Am Soc Nephrol, 2017, 28(2):421-430. DOI PMID
[12]	FRANCIS J M, BECK L H J R, SALANT D J. Membranous nephropathy:a journey from bench to bedside[J]. Am J Kidney Dis, 2016, 68(1):138-147. DOI URL
[13]	胡广. 血清抗PLA2R抗体在特发性膜性肾病诊断及病情评估中应用的可行性分析[D]. 南宁: 广西中医药大学, 2020.

样本	批内精密度					批间精密度
	CLIA			ELISA			CLIA			ELISA
		$\bar{x}$/ （RU/mL）	s/（RU/mL）	CV/ %		$\bar{x}$/ （RU/mL）	s/（RU/mL）	CV/ %		$\bar{x}$/ （RU/mL）	s/（RU/mL）	CV/ %	$\bar{x}$/ （RU/mL）	s/（RU/mL）	CV/ %
低值	16.34	0.20	1.23	12.33	1.01	8.18	16.04	0.42	2.59	13.65	1.18	8.67
高值	1 082.32	15.69	1.45	1 053.55	89.66	8.51	1 077.98	22.85	2.12	1 056.20	94.11	8.91

样本	批内精密度					批间精密度
	CLIA			ELISA			CLIA			ELISA
		$\bar{x}$/ （RU/mL）	s/（RU/mL）	CV/ %		$\bar{x}$/ （RU/mL）	s/（RU/mL）	CV/ %		$\bar{x}$/ （RU/mL）	s/（RU/mL）	CV/ %	$\bar{x}$/ （RU/mL）	s/（RU/mL）	CV/ %
低值	16.34	0.20	1.23	12.33	1.01	8.18	16.04	0.42	2.59	13.65	1.18	8.67
高值	1 082.32	15.69	1.45	1 053.55	89.66	8.51	1 077.98	22.85	2.12	1 056.20	94.11	8.91

ELISA	CLIA		合计
ELISA	阳性	阴性	合计
阳性	112	1	113
阴性	9	165	174
合计	121	166	287

ELISA	CLIA		合计
ELISA	阳性	阴性	合计
阳性	112	1	113
阴性	9	165	174
合计	121	166	287

组别	例数	CLIA/（RU/mL）	ELISA/（RU/mL）
PMN组	135	225.50±194.79	196.12±160.67
非PMN组	152	2.47±1.81	4.12±2.52
t值		6.06	2.46
P值		<0.01	<0.01

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

Figures/Tables 4

References 13

Related Articles 15

Recommended Articles

Metrics

[1]	GAO Zikang, CHEN Jing. Construction of a nomogram prediction model for the prognosis of patients with depressive disorder based on the characteristics of peripheral blood lymphocyte subsets [J]. Laboratory Medicine, 2025, 40(12): 1146-1152.
[2]	WANG Tian, ZHANG Yun, BAI Yi, ZHAI Weibin, ZHAO Hai. Roles of PIV，SII and NPAR in the diagnosis of spontaneous bacterial peritonitis in patients with liver cirrhosis and ascites [J]. Laboratory Medicine, 2025, 40(12): 1153-1158.
[3]	HUANG Ting, XU Yan, SHI Qingxing, PENG Ying. Roles of miR-944 and MARCH7 mRNA in prognosis assessment of non-small cell lung cancer patients [J]. Laboratory Medicine, 2025, 40(12): 1159-1164.
[4]	LI Minghong, MIN Cuili, GUO Qingbo, MA Lujuan. Predictive roles of serum 25（OH）D and SAA for the response to immunosuppressive therapy in autoimmune hepatitis [J]. Laboratory Medicine, 2025, 40(12): 1165-1170.
[5]	ZHEN Di, JIA Bin, MENG Xianyi. Roles of serum sPD-1 and sTWEAK levels in patients with ulcerative colitis in disease monitoring and prognosis assessment [J]. Laboratory Medicine, 2025, 40(12): 1171-1176.
[6]	ZHAO Yilin, XU Yan, YIN Hui. Roles of serum miR-145-5p，miR-200C-3p and miR-1290 in prognosis assessment of patients with papillary thyroid carcinoma [J]. Laboratory Medicine, 2025, 40(12): 1177-1182.
[7]	LI Song, XIANG Xu. Risk factors for poor prognosis in elderly patients with severe fever and thrombocytopenia syndrome and their clinical significance [J]. Laboratory Medicine, 2025, 40(12): 1183-1189.
[8]	CHANG Nan, WEI Yali, LU Qifeng, LI Tian, HOU Tingting, LI Yuan, ZHU Mengyu, SHEN Yajuan. A machine learning early warning model for acute promyelocytic leukemia based on blood cell analyzer parameters [J]. Laboratory Medicine, 2025, 40(12): 1190-1196.
[9]	. [J]. Laboratory Medicine, 2025, 40(12): 1197-1202.
[10]	. [J]. Laboratory Medicine, 2025, 40(12): 1216-1221.
[11]	. [J]. Laboratory Medicine, 2025, 40(12): 1222-1226.
[12]	BAO Wen. Application and prospect of microsatellite instability determination in tumor diagnosis and treatment [J]. Laboratory Medicine, 2025, 40(12): 1227-1231.
[13]	XIONG Ying, GUO Wei. From generic to personalized：the evolution and frontiers of indirect methods for establishing reference interval [J]. Laboratory Medicine, 2025, 40(11): 1035-1041.
[14]	CHEN Yanqin, FAN Lina, YANG Dagan. Six indirect method algorithms for establishing the reference range of serum cystatin C for adults in Hangzhou and consistency analysis [J]. Laboratory Medicine, 2025, 40(11): 1047-1052.
[15]	LIU Chunyan, NIU Shumin, DENG Zhaohui, LIANG Mengjie, ZHANG Xin. Establishing the reference ranges for AFP，CEA，CA72-4 and CA19-9 in Urumqi region by indirect method [J]. Laboratory Medicine, 2025, 40(11): 1053-1058.